Understanding the Market | QYUNS-B rises over 7% as the application for the marketing authorization of Ustekinumab injection has been approved

QYUNS-B rose over 7%, as of the time of writing, up 7.69%, priced at HKD 14, with a transaction volume of HKD 451,000. In terms of news, QYUNS announced that on November 5th, it received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA) for the listing application of Ustekinumab Injection (trade name: Stelara®, research code: QX001S/HDM3001) submitted by Zhenhua East China, which is used for the treatment of adult moderate to severe plaque psoriasis. QX001S was initially independently developed by the company, and in August 2020, the company reached a cooperation agreement with Zhenhua East China to jointly promote the Phase III clinical trial of QX001S, with Zhenhua East China as the marketing authorization holder responsible for commercialization in mainland China, and the company responsible for product manufacturing and supply. QX001S is the first product in the company's research pipeline to be approved for listing and is also the first approved biosimilar of Ustekinumab Injection in China